Trial Profile

A Phase I Study to Evaluate AVA004 in Patients with Advanced PD-L1 Positive Solid Tumours

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AVA-004 (Primary) ; AVA-004 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
Sponsors Avacta

Most Recent Events

10 Jun 2019 According to an Avacta media release, the company has selected the clinical development candidate AVA004, for first-time-in-human clinical trial of the Affimer platform.The company remains on track to submit an IND/CTA application for AVA004 by the end of 2020 and dosing of first patients shortly afterwards.
09 Oct 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com